New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

What it owns vs. what it owes End of fiscal 2025, Dec 31, 2025

Shareholders’ equity is 30.1% of the balance sheet. What is a balance sheet?

Dec 31, 2025 · total $62.3M

Owns

$14.5MLong-term assets
$1.5MOther short-term assets
$46.3MCash & short-term investments

Funded by

$18.8MShareholders’ equity
$43.5MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 30.1%.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Total current assets
47.76 78.82 117.96 197.04 325.07 317.18 165.78 33.40
Total non-current assets
14.52 23.60 32.59 46.51 30.01 10.82 12.84 —
Total Assets
62.28 102.41 150.55 243.55 355.08 328.01 178.61 33.46
Total current liabilities
23.08 19.36 16.34 18.35 29.50 21.18 3.68 0.31
Total non-current liabilities
20.44 21.79 22.92 23.83 6.92 2.12 231.19 —
Total liabilities
43.53 41.15 39.26 42.18 36.42 23.29 234.87 2.52
Common Equity (Total)
18.76 61.26 111.28 201.37 318.66 304.71 (56.25) (12.17)
Shareholders Equity (Total)
18.76 61.26 111.28 201.37 318.66 304.71 (56.25) (12.17)
Total Debt
— — — 27.11 — — — —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 12, 2026